Eur Urol:重点治疗后机器人辅助的根治性前列腺切除术的效果研究

2019-04-09 AlexYang MedSci原创

那些经历重点治疗(FT)后的前列腺癌(PC)局部复发患者,进行根治性前列腺切除术(RP)后的结果和毒性情况的相关研究很少。最近,有研究人员对进行抢救性机器人协助RP(S-RALP)的患者的围手术期,肿瘤和功能结果情况进行了鉴定,并确定了S-RALP失败的风险因素。研究是一个多中心的群体研究,包括了82名在FT后经历S-RALP的患者。所有的参与者均具有组织学确定的PC复发。研究发现,无进展生存在术

那些经历重点治疗(FT)后的前列腺癌(PC)局部复发患者,进行根治性前列腺切除术(RP)后的结果和毒性情况的相关研究很少。最近,有研究人员对进行抢救性机器人协助RP(S-RALP)的患者的围手术期,肿瘤和功能结果情况进行了鉴定,并确定了S-RALP失败的风险因素。

研究是一个多中心的群体研究,包括了82名在FT后经历S-RALP的患者。所有的参与者均具有组织学确定的PC复发。研究发现,无进展生存在术后的第12、24和36个月时分别为74%、48%和36%。12个月的可控率为83%,且不存在术中并发症和术后并发症。在多变量分析中,只有内场复发(HR 3.77,95%CI 1.11-12.85;p=0.03)和pT3b阶段(HR 5.0, 95% CI 1.53-16.39; p=0.008)是复发的独立预测因子。

最后,研究人员指出,他们的研究代表了FT后的抢救性手术情况,并且表明了该手术时安全的且与初始的RALP相比不增加毒性。另外,那些鉴定为FT后内场复发的患者可能出现表型恶化疾病,这些患者应该及时向医生咨询从而考虑多种方法治疗的可能。

原始出处:


本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (7)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1708848, encodeId=c9ba1e088487a, content=<a href='/topic/show?id=ffca32501e6' target=_blank style='color:#2F92EE;'>#前列腺切除#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32501, encryptionId=ffca32501e6, topicName=前列腺切除)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cbe731571573, createdName=1249898am25暂无昵称, createdTime=Mon Sep 02 06:55:00 CST 2019, time=2019-09-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1877141, encodeId=b3d518e7141d2, content=<a href='/topic/show?id=67c5319121e' target=_blank style='color:#2F92EE;'>#切除术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31912, encryptionId=67c5319121e, topicName=切除术)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9d8a96, createdName=doctorzheng, createdTime=Sat Nov 02 19:55:00 CST 2019, time=2019-11-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1322057, encodeId=155b132205e0a, content=<a href='/topic/show?id=890c611854e' target=_blank style='color:#2F92EE;'>#机器人#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=61185, encryptionId=890c611854e, topicName=机器人)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d139492, createdName=xue8602, createdTime=Thu Apr 11 03:55:00 CST 2019, time=2019-04-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1513322, encodeId=2c711513322fb, content=<a href='/topic/show?id=6a446120454' target=_blank style='color:#2F92EE;'>#机器人辅助#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=61204, encryptionId=6a446120454, topicName=机器人辅助)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=324410545094, createdName=124987a0m69(暂无昵称), createdTime=Thu Apr 11 03:55:00 CST 2019, time=2019-04-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1583176, encodeId=7dfd15831e68b, content=<a href='/topic/show?id=f6e1611840d' target=_blank style='color:#2F92EE;'>#机器#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=61184, encryptionId=f6e1611840d, topicName=机器)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=13dc16973127, createdName=ms6279672939590805, createdTime=Thu Apr 11 03:55:00 CST 2019, time=2019-04-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1586136, encodeId=763f158613646, content=<a href='/topic/show?id=38f8622191b' target=_blank style='color:#2F92EE;'>#根治#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62219, encryptionId=38f8622191b, topicName=根治)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=26d917348678, createdName=jeanqiuqiu, createdTime=Thu Apr 11 03:55:00 CST 2019, time=2019-04-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1046791, encodeId=db051046e9120, content=疗效只是效果的众多方面之一,还要看对患者的获益,包括生活质量等因素共同决定效果的, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=CHANGE, createdTime=Tue Apr 09 15:55:00 CST 2019, time=2019-04-09, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1708848, encodeId=c9ba1e088487a, content=<a href='/topic/show?id=ffca32501e6' target=_blank style='color:#2F92EE;'>#前列腺切除#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32501, encryptionId=ffca32501e6, topicName=前列腺切除)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cbe731571573, createdName=1249898am25暂无昵称, createdTime=Mon Sep 02 06:55:00 CST 2019, time=2019-09-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1877141, encodeId=b3d518e7141d2, content=<a href='/topic/show?id=67c5319121e' target=_blank style='color:#2F92EE;'>#切除术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31912, encryptionId=67c5319121e, topicName=切除术)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9d8a96, createdName=doctorzheng, createdTime=Sat Nov 02 19:55:00 CST 2019, time=2019-11-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1322057, encodeId=155b132205e0a, content=<a href='/topic/show?id=890c611854e' target=_blank style='color:#2F92EE;'>#机器人#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=61185, encryptionId=890c611854e, topicName=机器人)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d139492, createdName=xue8602, createdTime=Thu Apr 11 03:55:00 CST 2019, time=2019-04-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1513322, encodeId=2c711513322fb, content=<a href='/topic/show?id=6a446120454' target=_blank style='color:#2F92EE;'>#机器人辅助#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=61204, encryptionId=6a446120454, topicName=机器人辅助)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=324410545094, createdName=124987a0m69(暂无昵称), createdTime=Thu Apr 11 03:55:00 CST 2019, time=2019-04-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1583176, encodeId=7dfd15831e68b, content=<a href='/topic/show?id=f6e1611840d' target=_blank style='color:#2F92EE;'>#机器#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=61184, encryptionId=f6e1611840d, topicName=机器)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=13dc16973127, createdName=ms6279672939590805, createdTime=Thu Apr 11 03:55:00 CST 2019, time=2019-04-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1586136, encodeId=763f158613646, content=<a href='/topic/show?id=38f8622191b' target=_blank style='color:#2F92EE;'>#根治#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62219, encryptionId=38f8622191b, topicName=根治)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=26d917348678, createdName=jeanqiuqiu, createdTime=Thu Apr 11 03:55:00 CST 2019, time=2019-04-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1046791, encodeId=db051046e9120, content=疗效只是效果的众多方面之一,还要看对患者的获益,包括生活质量等因素共同决定效果的, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=CHANGE, createdTime=Tue Apr 09 15:55:00 CST 2019, time=2019-04-09, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1708848, encodeId=c9ba1e088487a, content=<a href='/topic/show?id=ffca32501e6' target=_blank style='color:#2F92EE;'>#前列腺切除#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32501, encryptionId=ffca32501e6, topicName=前列腺切除)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cbe731571573, createdName=1249898am25暂无昵称, createdTime=Mon Sep 02 06:55:00 CST 2019, time=2019-09-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1877141, encodeId=b3d518e7141d2, content=<a href='/topic/show?id=67c5319121e' target=_blank style='color:#2F92EE;'>#切除术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31912, encryptionId=67c5319121e, topicName=切除术)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9d8a96, createdName=doctorzheng, createdTime=Sat Nov 02 19:55:00 CST 2019, time=2019-11-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1322057, encodeId=155b132205e0a, content=<a href='/topic/show?id=890c611854e' target=_blank style='color:#2F92EE;'>#机器人#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=61185, encryptionId=890c611854e, topicName=机器人)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d139492, createdName=xue8602, createdTime=Thu Apr 11 03:55:00 CST 2019, time=2019-04-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1513322, encodeId=2c711513322fb, content=<a href='/topic/show?id=6a446120454' target=_blank style='color:#2F92EE;'>#机器人辅助#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=61204, encryptionId=6a446120454, topicName=机器人辅助)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=324410545094, createdName=124987a0m69(暂无昵称), createdTime=Thu Apr 11 03:55:00 CST 2019, time=2019-04-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1583176, encodeId=7dfd15831e68b, content=<a href='/topic/show?id=f6e1611840d' target=_blank style='color:#2F92EE;'>#机器#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=61184, encryptionId=f6e1611840d, topicName=机器)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=13dc16973127, createdName=ms6279672939590805, createdTime=Thu Apr 11 03:55:00 CST 2019, time=2019-04-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1586136, encodeId=763f158613646, content=<a href='/topic/show?id=38f8622191b' target=_blank style='color:#2F92EE;'>#根治#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62219, encryptionId=38f8622191b, topicName=根治)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=26d917348678, createdName=jeanqiuqiu, createdTime=Thu Apr 11 03:55:00 CST 2019, time=2019-04-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1046791, encodeId=db051046e9120, content=疗效只是效果的众多方面之一,还要看对患者的获益,包括生活质量等因素共同决定效果的, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=CHANGE, createdTime=Tue Apr 09 15:55:00 CST 2019, time=2019-04-09, status=1, ipAttribution=)]
    2019-04-11 xue8602
  4. [GetPortalCommentsPageByObjectIdResponse(id=1708848, encodeId=c9ba1e088487a, content=<a href='/topic/show?id=ffca32501e6' target=_blank style='color:#2F92EE;'>#前列腺切除#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32501, encryptionId=ffca32501e6, topicName=前列腺切除)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cbe731571573, createdName=1249898am25暂无昵称, createdTime=Mon Sep 02 06:55:00 CST 2019, time=2019-09-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1877141, encodeId=b3d518e7141d2, content=<a href='/topic/show?id=67c5319121e' target=_blank style='color:#2F92EE;'>#切除术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31912, encryptionId=67c5319121e, topicName=切除术)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9d8a96, createdName=doctorzheng, createdTime=Sat Nov 02 19:55:00 CST 2019, time=2019-11-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1322057, encodeId=155b132205e0a, content=<a href='/topic/show?id=890c611854e' target=_blank style='color:#2F92EE;'>#机器人#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=61185, encryptionId=890c611854e, topicName=机器人)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d139492, createdName=xue8602, createdTime=Thu Apr 11 03:55:00 CST 2019, time=2019-04-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1513322, encodeId=2c711513322fb, content=<a href='/topic/show?id=6a446120454' target=_blank style='color:#2F92EE;'>#机器人辅助#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=61204, encryptionId=6a446120454, topicName=机器人辅助)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=324410545094, createdName=124987a0m69(暂无昵称), createdTime=Thu Apr 11 03:55:00 CST 2019, time=2019-04-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1583176, encodeId=7dfd15831e68b, content=<a href='/topic/show?id=f6e1611840d' target=_blank style='color:#2F92EE;'>#机器#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=61184, encryptionId=f6e1611840d, topicName=机器)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=13dc16973127, createdName=ms6279672939590805, createdTime=Thu Apr 11 03:55:00 CST 2019, time=2019-04-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1586136, encodeId=763f158613646, content=<a href='/topic/show?id=38f8622191b' target=_blank style='color:#2F92EE;'>#根治#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62219, encryptionId=38f8622191b, topicName=根治)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=26d917348678, createdName=jeanqiuqiu, createdTime=Thu Apr 11 03:55:00 CST 2019, time=2019-04-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1046791, encodeId=db051046e9120, content=疗效只是效果的众多方面之一,还要看对患者的获益,包括生活质量等因素共同决定效果的, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=CHANGE, createdTime=Tue Apr 09 15:55:00 CST 2019, time=2019-04-09, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1708848, encodeId=c9ba1e088487a, content=<a href='/topic/show?id=ffca32501e6' target=_blank style='color:#2F92EE;'>#前列腺切除#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32501, encryptionId=ffca32501e6, topicName=前列腺切除)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cbe731571573, createdName=1249898am25暂无昵称, createdTime=Mon Sep 02 06:55:00 CST 2019, time=2019-09-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1877141, encodeId=b3d518e7141d2, content=<a href='/topic/show?id=67c5319121e' target=_blank style='color:#2F92EE;'>#切除术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31912, encryptionId=67c5319121e, topicName=切除术)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9d8a96, createdName=doctorzheng, createdTime=Sat Nov 02 19:55:00 CST 2019, time=2019-11-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1322057, encodeId=155b132205e0a, content=<a href='/topic/show?id=890c611854e' target=_blank style='color:#2F92EE;'>#机器人#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=61185, encryptionId=890c611854e, topicName=机器人)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d139492, createdName=xue8602, createdTime=Thu Apr 11 03:55:00 CST 2019, time=2019-04-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1513322, encodeId=2c711513322fb, content=<a href='/topic/show?id=6a446120454' target=_blank style='color:#2F92EE;'>#机器人辅助#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=61204, encryptionId=6a446120454, topicName=机器人辅助)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=324410545094, createdName=124987a0m69(暂无昵称), createdTime=Thu Apr 11 03:55:00 CST 2019, time=2019-04-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1583176, encodeId=7dfd15831e68b, content=<a href='/topic/show?id=f6e1611840d' target=_blank style='color:#2F92EE;'>#机器#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=61184, encryptionId=f6e1611840d, topicName=机器)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=13dc16973127, createdName=ms6279672939590805, createdTime=Thu Apr 11 03:55:00 CST 2019, time=2019-04-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1586136, encodeId=763f158613646, content=<a href='/topic/show?id=38f8622191b' target=_blank style='color:#2F92EE;'>#根治#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62219, encryptionId=38f8622191b, topicName=根治)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=26d917348678, createdName=jeanqiuqiu, createdTime=Thu Apr 11 03:55:00 CST 2019, time=2019-04-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1046791, encodeId=db051046e9120, content=疗效只是效果的众多方面之一,还要看对患者的获益,包括生活质量等因素共同决定效果的, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=CHANGE, createdTime=Tue Apr 09 15:55:00 CST 2019, time=2019-04-09, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=1708848, encodeId=c9ba1e088487a, content=<a href='/topic/show?id=ffca32501e6' target=_blank style='color:#2F92EE;'>#前列腺切除#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32501, encryptionId=ffca32501e6, topicName=前列腺切除)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cbe731571573, createdName=1249898am25暂无昵称, createdTime=Mon Sep 02 06:55:00 CST 2019, time=2019-09-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1877141, encodeId=b3d518e7141d2, content=<a href='/topic/show?id=67c5319121e' target=_blank style='color:#2F92EE;'>#切除术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31912, encryptionId=67c5319121e, topicName=切除术)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9d8a96, createdName=doctorzheng, createdTime=Sat Nov 02 19:55:00 CST 2019, time=2019-11-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1322057, encodeId=155b132205e0a, content=<a href='/topic/show?id=890c611854e' target=_blank style='color:#2F92EE;'>#机器人#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=61185, encryptionId=890c611854e, topicName=机器人)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d139492, createdName=xue8602, createdTime=Thu Apr 11 03:55:00 CST 2019, time=2019-04-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1513322, encodeId=2c711513322fb, content=<a href='/topic/show?id=6a446120454' target=_blank style='color:#2F92EE;'>#机器人辅助#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=61204, encryptionId=6a446120454, topicName=机器人辅助)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=324410545094, createdName=124987a0m69(暂无昵称), createdTime=Thu Apr 11 03:55:00 CST 2019, time=2019-04-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1583176, encodeId=7dfd15831e68b, content=<a href='/topic/show?id=f6e1611840d' target=_blank style='color:#2F92EE;'>#机器#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=61184, encryptionId=f6e1611840d, topicName=机器)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=13dc16973127, createdName=ms6279672939590805, createdTime=Thu Apr 11 03:55:00 CST 2019, time=2019-04-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1586136, encodeId=763f158613646, content=<a href='/topic/show?id=38f8622191b' target=_blank style='color:#2F92EE;'>#根治#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62219, encryptionId=38f8622191b, topicName=根治)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=26d917348678, createdName=jeanqiuqiu, createdTime=Thu Apr 11 03:55:00 CST 2019, time=2019-04-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1046791, encodeId=db051046e9120, content=疗效只是效果的众多方面之一,还要看对患者的获益,包括生活质量等因素共同决定效果的, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=CHANGE, createdTime=Tue Apr 09 15:55:00 CST 2019, time=2019-04-09, status=1, ipAttribution=)]
    2019-04-11 jeanqiuqiu
  7. [GetPortalCommentsPageByObjectIdResponse(id=1708848, encodeId=c9ba1e088487a, content=<a href='/topic/show?id=ffca32501e6' target=_blank style='color:#2F92EE;'>#前列腺切除#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32501, encryptionId=ffca32501e6, topicName=前列腺切除)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cbe731571573, createdName=1249898am25暂无昵称, createdTime=Mon Sep 02 06:55:00 CST 2019, time=2019-09-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1877141, encodeId=b3d518e7141d2, content=<a href='/topic/show?id=67c5319121e' target=_blank style='color:#2F92EE;'>#切除术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31912, encryptionId=67c5319121e, topicName=切除术)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9d8a96, createdName=doctorzheng, createdTime=Sat Nov 02 19:55:00 CST 2019, time=2019-11-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1322057, encodeId=155b132205e0a, content=<a href='/topic/show?id=890c611854e' target=_blank style='color:#2F92EE;'>#机器人#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=61185, encryptionId=890c611854e, topicName=机器人)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d139492, createdName=xue8602, createdTime=Thu Apr 11 03:55:00 CST 2019, time=2019-04-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1513322, encodeId=2c711513322fb, content=<a href='/topic/show?id=6a446120454' target=_blank style='color:#2F92EE;'>#机器人辅助#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=61204, encryptionId=6a446120454, topicName=机器人辅助)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=324410545094, createdName=124987a0m69(暂无昵称), createdTime=Thu Apr 11 03:55:00 CST 2019, time=2019-04-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1583176, encodeId=7dfd15831e68b, content=<a href='/topic/show?id=f6e1611840d' target=_blank style='color:#2F92EE;'>#机器#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=61184, encryptionId=f6e1611840d, topicName=机器)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=13dc16973127, createdName=ms6279672939590805, createdTime=Thu Apr 11 03:55:00 CST 2019, time=2019-04-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1586136, encodeId=763f158613646, content=<a href='/topic/show?id=38f8622191b' target=_blank style='color:#2F92EE;'>#根治#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62219, encryptionId=38f8622191b, topicName=根治)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=26d917348678, createdName=jeanqiuqiu, createdTime=Thu Apr 11 03:55:00 CST 2019, time=2019-04-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1046791, encodeId=db051046e9120, content=疗效只是效果的众多方面之一,还要看对患者的获益,包括生活质量等因素共同决定效果的, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=CHANGE, createdTime=Tue Apr 09 15:55:00 CST 2019, time=2019-04-09, status=1, ipAttribution=)]
    2019-04-09 CHANGE

    疗效只是效果的众多方面之一,还要看对患者的获益,包括生活质量等因素共同决定效果的

    0

相关资讯

NCCN临床实践指南:前列腺癌(2019.V1)

2019年3月,美国国家综合癌症网络(NCCN)发布了前列腺癌指南2019年第1版,指南主要内容涉及: 指南更新摘要 初始前列腺癌诊断 非常低风险:初始治疗、辅助治疗 低风险:初始治疗、辅助治疗 中间风险:初始治疗、辅助治疗 高风险,极高风险:初始治疗、辅助治疗 检测,复发 前列腺切除术失败 放射治疗复发 系统治疗 M1 CRPC随后系统治疗 生存寿命评估原则 影像检查原则 积极监测和观察原则 放

EBioMedicine:细胞分裂周期蛋白20(CDC20)能够促使前列腺癌的恶化

细胞分裂周期蛋白20(CDC20)在恶性肿瘤中经常过表达并且还参与了造血干细胞的分化过程。然而,CDC20在前列腺癌类干细胞(CSCs)中中的作用仍旧所知较少。最近,有研究人员通过免疫组化染色对前列腺癌样本中的CDC20、CD44和β-连环蛋白表达进行了分析,并通过实时定量PCR、球体形成、体内外有限稀释试验对CDC20对类干细胞特性的前列腺CSCs作用进行了评估。研究发现,CDC20与前列腺癌的

Oncogenesis:CUL4B能够通过与SOX4形成正反馈循环促进前列腺癌恶化

怎样从恶性疾病中区分无痛性疾病在前列腺癌(PCa)的治疗中仍旧是一个巨大的挑战。Cullin 4B (CUL4B)是一种支架蛋白并且在多种人类恶性肿瘤中表现出了致瘤活性。最近,有研究人员利用PCa组织样本、细胞系和异种种植模型确定了是否CUL4B能够导致PCa恶化和转移。研究发现,CUL4B的表达与PCa的恶化过程相关。CUL4B的表达能够促进PCa细胞的增殖、上皮间质转化和PCa细胞的转移,而C

EBioMedicine:前列腺癌治疗药物新发现

基因组规模的代谢模型(GEMs)为癌症代谢提供了新的认识,并且已经用于鉴定潜在的生物标记和药物靶标。药物重定位是一种既省时又省力的药物发现的方法,并且可以与GEMs一起用于癌症的有效治疗。最近,有研究人员构建了一个前列腺癌(PRAD)特异性GEM,用来探索前列腺癌代谢,并且探索新的可以用于有效癌症治疗的药物。研究人员通过使用前列腺癌GEM模型对多于1000中不同的药物进行了整体的基因表达分析,并预

Prostate Cancer P D: 前列腺癌SLCO基因表达与格林森等级和雄激素阻断治疗后变化相关性分析

雄激素阻断治疗(ADT)后,SLCO编码的转运蛋白与去势难治性前列腺癌(CRPC)的恶化相关。尽管比CRPC组织中的表达水平更低,SLCO编码的转运蛋白可能在原发性前列腺癌(PCa)对ADT和生化复发响应中具有作用。最近,有研究人员系统性的探索了11个人类SLCO基因的表达在正常的前列腺(NP)和ADT治疗和未治疗的原发性PCa组织中的表达情况,包括了阿比特龙新辅助治疗的肿瘤。研究发现,在PCa中

Prostate:未经激素治疗前列腺癌中tSTAT3、pSTAT3 727和pSTAT3 705的表达研究

信号转导和激活转录因子3(STAT3)途径在一些恶性肿瘤中持续性的激活,其中包括了前列腺癌(PCa)。最近,有研究人员在2个未经激素治疗的局部PCa患者群体的组织芯片中,调查了总STAT3(tSTAT3)和2种激活形式的磷酸化STAT3(pSTAT3 727和pSTAT3 705)的表达情况,并且分析了表达与疾病结果的相关性情况。研究发现,tSTAT3、pSTAT3 727和pSTAT3 705在